Let’s talk about tech
As people living with sight loss we are constantly looking for solutions to make our lives easier without too much effort or cost writes Jonathan Abro.
Search results
As people living with sight loss we are constantly looking for solutions to make our lives easier without too much effort or cost writes Jonathan Abro.
In this article, we hear Colin's story and the reasons why he has hope for the future.
Various dates and locations available. Skydiving is an exhilarating experience, and you can do this while supporting our cause.
Whether you are a professional looking for practical information for yourself, or practical or emotional support for your clients, online, by phone or face-to-face, we're here to help. All of our services are free to access and offered in a range of accessible formats.
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
Do you know your facts from your fiction? Host a quiz for Retina UK.
Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.